Hereditary Angioedema (HAE) Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Germany, Canada, India - Size and Forecast 2024-2028

Hereditary Angioedema (Hae) Therapeutics Market Size 2024-2028

The hereditary angioedema (hae) therapeutics market size is forecast to increase by USD 2.19 billion at a CAGR of 10.59% between 2023 and 2028.

What will be the Size of the Hereditary Angioedema (Hae) Therapeutics Market During the Forecast Period?

 Request Free Sample

How is this Hereditary Angioedema (Hae) Therapeutics Industry segmented and which is the largest segment?

The hereditary angioedema (hae) therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• End-user
  • Hospital pharmacies
  • Retail pharmacies
  • E-commerce
• Product
  • C1-esterase inhibitor
  • Bradykinin B2 receptor antagonist
  • Kallikrein inhibitor
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
  • Asia
    • China
    • India
  • Rest of World (ROW)

By End-user Insights

The hospital pharmacies segment is estimated to witness significant growth during the forecast period. Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks affecting various body parts including hands, feet, face, and airways. HAE is caused by dysfunctional C1 inhibitor proteins due to a family history or spontaneous mutation of the C1 inhibitor gene. Two main types, Type I HAE and Type II HAE, differ In the presence or absence of functional C1 inhibitor. HAE patients experience debilitating symptoms, leading to reduced quality of life and potential misdiagnosis with allergies or other conditions. The global hereditary angioedema therapeutics market caters to the demand for medications that address this complex condition.

Hospital pharmacies play a crucial role in procuring and stocking various treatments such as C1 esterase inhibitors, Kallikrein inhibitors, and intravenous or subcutaneous administration options including Cinryze, SAJAZIR Injection, Kalbitor, Ruconest, Icatibant, Firazyr, Berinert, Orladeyo, Haegarda, and Takhzyro. Physicians, including dermatologists, gastroenterologists, and clinical allergists, rely on these medications for HAE prophylaxis and treatment. Ensuring a reliable supply of these therapies is essential for hospital pharmacies to meet the needs of HAE patients. By actively sourcing from reputable suppliers, they can maintain sufficient stock and help prevent potential complications, such as misdiagnosis, allergic reactions, or delayed treatment. The rare diseases industry continues to develop new medications, such as lanadelumab monoclonal antibody and pipeline medications, to improve the lives of HAE patients.

Get a glance at the market report of various segments Request Free Sample

The Hospital pharmacies segment was valued at USD 1.08 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

Hereditary Angioedema (HAE) is a rare genetic disorder marked by recurring edema attacks in various body parts, such as hands, feet, face, and airways. North America dominates the global HAE therapeutics market due to its advanced healthcare infrastructure, substantial research investments, and high disease prevalence. The region's robust healthcare system, world-class medical facilities, and a well-established pharmaceutical industry enable early diagnosis and effective disease management. HAE is caused by dysfunctional C1 inhibitor proteins in Type I and Type II HAE or a deficiency of C1 inhibitor in Type III HAE due to genetic mutations or spontaneous events. Therapies like donidalorsen, cinryze, sajazir injection, and lanadelumab monoclonal antibody are used to prevent and manage HAE attacks.

Specialized clinics and trained healthcare professionals ensure accurate diagnosis and timely intervention, improving patient quality of life. Key market players focus on developing new therapies, including oral medications and subcutaneous injections, to cater to diverse patient needs.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Hereditary Angioedema (Hae) Therapeutics Industry?

• Increasing prevalence of hereditary angioedema is the key driver of the market.Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of edema, or swelling, in various parts of the body, including the hands, feet, face, and airways. This disorder is caused by dysfunctions In the immune system that affect the synthesis of the C1 inhibitor protein, which plays a crucial role in regulating the complement system and preventing the activation of blood vessels. HAE can be classified into three types: Type I, Type II, and Type III, each with distinct underlying causes. Type I HAE is caused by a deficiency of C1 inhibitor, while Type II HAE is characterized by dysfunctional C1 inhibitor.

  Type III HAE is caused by a combination of both deficiency and dysfunction. Despite being considered a rare disease, the prevalence of HAE has been increasing due to improved awareness and diagnosis. In the past, HAE was frequently misdiagnosed or undiagnosed, leading to an underestimation of its prevalence. However, with increased awareness among healthcare professionals and improved diagnostic tools, more cases are being identified and reported. Currently, there are several therapeutic options available for managing HAE attacks, including C1 esterase inhibitor, Kallikrein inhibitor, and attenuated androgens. Intravenous and subcutaneous treatments, such as Cinryze, SAJAZIR Injection, Bradykinin B2 receptor antagonists like Kalbitor, and Ruconest, are used for acute attacks.

  Long-term prophylaxis options include oral medications like lanadelumab monoclonal antibody, intravenous treatments like Icatibant and Berinert, and subcutaneous injections like Orladeyo, Haegarda, and Takhzyro. Healthcare professionals, including dermatologists, gastroenterologists, and clinical allergists, play a crucial role in diagnosing and managing HAE. Misdiagnosis is common, with conditions such as allergic reactions, appendicitis, and irritable bowel syndrome often being mistaken for HAE. Therefore, it is essential for healthcare professionals to be aware of the signs and symptoms of HAE and to consider it as a differential diagnosis for patients presenting with unexplained edema. The rare diseases industry has seen significant growth in recent years, with several pipeline medications in development for HAE.

  These include drugs like tranexamic acid, intravenous treatments, and ACE inhibitors. While these medications offer promise for managing HAE, it is essential to ensure their safety and efficacy through rigorous clinical trials and regulatory approval processes. In conclusion, HAE is a rare genetic disorder that affects various parts of the body, leading to recurrent episodes of edema. Its prevalence has been increasing due to improved awareness and diagnosis. Several therapeutic options are available for managing HAE attacks and preventing future episodes, including intravenous and subcutaneous treatments, oral medications, and prophylaxis options. Healthcare professionals play a crucial role in diagnosing and managing HAE, and the rare diseases industry continues to develop new treatments for this condition.

What are the market trends shaping the Hereditary Angioedema (Hae) Therapeutics market?

• Growing demand for personalized medicine is the upcoming market trend.The market is experiencing growth due to the rising prevalence of this rare genetic condition and the demand for more effective treatments. HAE is characterized by recurrent episodes of edema, or swelling, in various parts of the body, including the hands, feet, face, airways, and gastrointestinal tract. This disorder can lead to significant pain, discomfort, and functional impairment. Two main types of HAE exist: Type I, which is caused by a dysfunctional C1 inhibitor protein, and Type II, which is caused by a deficiency in C1 inhibitor. Both types result In the uncontrolled activation of the immune system, leading to the release of various substances that cause blood vessels to leak fluid.

  Traditional treatments for HAE have focused on managing symptoms and preventing severe attacks through the use of donidalorsen, a synthetic form of the missing or dysfunctional protein, or intravenous C1 inhibitor. However, recent advancements in personalized medicine have led to the development of new therapeutic options, including oral and subcutaneous medications, such as lanadelumab monoclonal antibody and Kallikrein inhibitors. These new treatments offer several advantages over traditional options, including greater convenience, improved efficacy, and a reduced risk of allergic reactions or other side effects. Additionally, they may help to prevent misdiagnosis and improve the overall quality of life for patients with HAE.

  Despite these advancements, challenges remain In the HAE therapeutics market, including the need for increased awareness and education among physicians, including dermatologists, gastroenterologists, and clinical allergists, as well as the high cost of these new treatments and the need for ongoing research and development to address the unique needs of different patient populations. In summary, the global HAE therapeutics market is witnessing growth due to the increasing prevalence of this rare disorder and the demand for more effective and personalized treatment options. While challenges remain, advancements in personalized medicine offer new possibilities for improving the lives of patients with HAE.

What challenges does the Hereditary Angioedema (Hae) Therapeutics Industry face during its growth?

• High cost associated with the development and production of hereditary angioedema therapeutics is a key challenge affecting the industry growth.The market has witnessed significant progress, providing relief to patients afflicted by this rare genetic condition. HAE is characterized by episodes of edema, or swelling, affecting various parts of the body including hands, feet, face, and airways. This disorder is caused by dysfunctional proteins In the immune system, leading to the activation of the complement system and the release of various mediators that cause edema. HAE is classified into three types: Type I HAE, caused by a deficiency in C1 inhibitor; Type II HAE, caused by dysfunctional C1 inhibitor; and Type III HAE, caused by a spontaneous mutation In the C1 inhibitor gene.

  Despite these advancements, the high cost of developing and producing HAE therapeutics remains a challenge. The process of bringing a new therapy to market involves substantial investments in preclinical studies, formulation development, testing, and regulatory submissions. Clinical trials, which range from initial safety assessments to large-scale efficacy studies, also contribute significantly to the overall cost. HAE therapeutics include C1 inhibitor, Kallikrein inhibitor, and attenuated androgens. These drugs come in various forms such as intravenous, subcutaneous, and oral. Some of the marketed therapies include Cinryze, SAJAZIR Injection, Bradykinin B2 receptor antagonists like Kalbitor, and Ruconest. Newer drugs like lanadelumab monoclonal antibody and pipeline medications offer potential solutions to address the unmet needs In the rare illnesses industry.

  Physicians, including dermatologists, gastroenterologists, and clinical allergists, play a crucial role in diagnosing and managing HAE. Misdiagnosis is common due to the non-specific symptoms and the lack of awareness among healthcare professionals. Patients may also experience allergic reactions or complications like appendicitis during treatment. The market for HAE therapeutics is diverse, with various drug classes and delivery methods. Intravenous treatments like C1 esterase inhibitor and Kallikrein inhibitors are commonly used for acute attacks. Subcutaneous injections like Icatibant, Firazyr, Berinert, Orladeyo, Haegarda, and Takhzyro offer convenience and longer-term protection. Other treatments include tranexamic acid, intravenous treatments like ACE inhibitors, and drugs for managing complications like allergies and irritable bowel syndrome.

  The high cost of developing and producing HAE therapeutics is a significant challenge, but the potential benefits to patients and their quality of life make the investment worthwhile. Continued research and innovation in this field will help improve the lives of those affected by this rare condition.

Exclusive Customer Landscape

The hereditary angioedema (hae) therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the hereditary angioedema (hae) therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, hereditary angioedema (hae) therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

Adverum Biotechnologies Inc - The market has seen significant advancements, with companies progressing In the development of novel treatments. One such innovation is ADVM-053, which has received approval from the Food and Drug Administration (FDA) and the Orphan Drug Designation (ODD). This gene therapy candidate is currently undergoing preclinical treatment, holding potential for addressing the unmet medical needs of HAE patients.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Adverum Biotechnologies Inc
• Arrowhead Pharmaceuticals Inc.
• Attune Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• BioMarin Pharmaceutical Inc.
• CENTOGENE NV
• Cipla Inc.
• CSL Ltd.
• Diapharma Group Inc.
• Intellia Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Pharming Group NV
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Hereditary Angioedema (HAE), a rare and often misunderstood condition, is characterized by recurrent episodes of edema, or swelling, affecting various parts of the body, including the hands, feet, face, and airways. This disorder is caused by dysfunctions In the immune system that result In the excessive activation of the complement system, leading to the release of various mediators and the subsequent swelling. Two main types of HAE exist: Type I and Type III. Type I HAE is caused by a deficiency in C1 inhibitor, a protein essential for regulating the complement system. In contrast, Type III HAE is characterized by dysfunctional C1 inhibitor, which still gets produced but fails to function properly.

Both types result in uncontrolled activation of the complement system and the subsequent edema attacks. The prevalence of HAE is relatively low, with estimates suggesting that approximately 1 in 50,000 to 1 in 100,000 people are affected. Despite its rarity, HAE significantly impacts the quality of life of those affected, with frequent and often spontaneous attacks leading to significant morbidity and even mortality in severe cases. Therapies for HAE aim to prevent or rapidly treat the edema attacks. Various options exist, including intravenous and subcutaneous treatments, as well as oral medications. C1 inhibitor replacement therapies, such as Cinryze, Sajazir injection, Berinert, Orladeyo, Haegarda, and Takhzyro, are commonly used for prophylaxis and acute treatment.

These medications work by either replacing the deficient C1 inhibitor or inhibiting the complement system in other ways. Kallikrein inhibitors, such as Kalbitor and Icatibant, are another class of drugs used for the treatment of HAE. These medications inhibit the activation of the complement system by blocking the enzyme kallikrein, which plays a role In the production of bradykinin, a potent mediator of edema. Despite the availability of these therapies, challenges remain. Misdiagnosis is common due to the nonspecific symptoms and the lack of awareness among healthcare professionals. Moreover, the high cost of these treatments and the need for frequent administration can pose significant challenges for patients and healthcare systems.

The rare diseases industry continues to invest In the development of new therapies for HAE and other rare illnesses. Pipeline medications, such as Lanadelumab monoclonal antibody, show promise in preventing HAE attacks by blocking the activation of the complement system. Attenuated androgens and Tranexamic acid are also being explored as potential treatments for HAE. Physicians, dermatologists, gastroenterologists, and clinical allergists play crucial roles In the diagnosis and management of HAE. A better understanding of the disease and the available therapeutic options is essential for improving the quality of life of those affected. In conclusion, HAE is a rare and complex disorder characterized by recurrent edema attacks caused by dysfunctions In the immune system.

Various therapeutic options, including C1 inhibitor replacement therapies and kallikrein inhibitors, are available for the prevention and treatment of HAE. Challenges remain, including misdiagnosis, high cost, and the need for frequent administration. The rare diseases industry continues to invest In the development of new therapies, offering hope for those affected by this condition.

Request Free Sample

What are the Key Data Covered in this Hereditary Angioedema (Hae) Therapeutics Market Research and Growth Report?

• CAGR of the Hereditary Angioedema (Hae) Therapeutics industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the hereditary angioedema (hae) therapeutics market growth of industry companies

We can help! Our analysts can customize this hereditary angioedema (hae) therapeutics market research report to meet your requirements.

Get in touch